Tiziana Life Sciences upbeat on potential for coronavirus treatment

0
25
  • Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences
  • Tiziana Life Sciences welcomes license deal for foralumab in CAR T cell therapy
Tiziana Life Sciences - Tiziana Life Sciences upbeat on potential for coronavirus treatment

Quick facts: Tiziana Life Sciences PLC

Follow

View company profile

Tiziana Life Sciences is a clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver.

Its clinical pipeline includes drug assets for Crohn’s Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma.

Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

02 Sep 2021

Shares in (NASDAQ:TLSA, ) raced 20% higher in the opening minutes of trading on Wall Street after the group inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL).

The tie-up takes it into the exciting arena of CAR-T therapy with the pair looking to use Tiziana’s foralumab monoclonal antibody (mAb) to enhance the next generation of cancer treatments.

The stock jumped 33 cents at the open to US$1.98.

has believes that might just be the start of the story and reckons the US traded ADR shares may be worth US$7.50 each.

Read more

02 Sep 2021

(, ) said it has inked an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) to explore the use of Tiziana’s foralumab monoclonal antibody (mAb) to enhance the next generation of CAR-T therapies.

CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene (now owned by Bristol Myers Squibb) and Gilead Sciences () underscore the interest in this emerging area of biotechnology.

Read more

20 Aug 2021

(, , , ) told investors it has formally begun its strategic plan to change its corporate structure.

It has established a Bermuda-incorporated company Tiziana Life Sciences Ltd which is the ultimate parent company of the Tiziana Group.

Read more

02 Sep 2021

(, , , )’s Dr Kunwar Shailubhai speaks to Proactive following the news of a License Agreement with Precision BioSciences Inc to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties for foralumab.

22 Sep 2021

Tiziana Life Sciences delivers its fully human therapeutic antibody, foralumab, to the gut or nose mucosal surfaces aiming to modulate the immune response. This might help to control various autoimmune diseases such as Crohn’s and Multiple Sclerosis (MS).

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: A different approach, tackling disease using a safe,…

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)’s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come.


The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal…

12 hours, 34 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here